Daré Bioscience Reports Q3 2026 Financial Results with Improved Net Loss and New Product Revenue

Daré Bioscience (DARE) reported its third-quarter 2026 financial results, highlighting a reduction in net loss to $3.2 million compared to $3.6 million in the prior year period. The company generated $48,000 in total revenue, driven by research and development services and initial sales of Flora Sync LF5 following its July 2026 launch. The company continues to leverage significant nondilutive grant funding, reporting $4.7 million in contra-R&D expenses for the quarter. Key upcoming milestones include top-line data from the Ovaprene Phase III trial and DARE-HPV Phase II study both expected in 2027, alongside a planned retail expansion of Flora Sync LF5 to Amazon in early 2027.

9 articles from 4 sources · updated

Coverage